Small molecule · Inhibitor of dihydroorotate dehydrogenase (DHODH) · developed by Sanofi Aventis Us
Teriflunomide is an oral immunomodulatory small molecule that inhibits dihydroorotate dehydrogenase, a mitochondrial enzyme in de novo pyrimidine synthesis, which may reduce the number of activated lymphocytes in the central nervous system. It is studied in multiple sclerosis.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Feb 20, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07930624 | Phase 3 | Multiple Sclerosis | Not yet recruiting | SNY |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Multiple Sclerosis
Updated Nov 15, 2026. Something wrong or missing? Report it on the SNY page.
See SNY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
SNY catalysts and pipeline →